首页 > 市场调查报告书 > 製药

再生医学细胞疗法

市场调查报告书

商品编码

1518527

基因治疗临床试验服务市场 - 按服务（临床试验设计和规划、供应和物流、监管、数据管理和生物统计）、治疗领域（肿瘤、肌肉骨骼、CVD）、最终用户 - 全球预测（2024 - 2032）

Gene Therapy Clinical Trial Services Market - By Services (Clinical Trial Design & Planning, Supply & Logistics, Regulatory, Data Management & Biostatistics), Therapeutic Areas (Oncology, Musculoskeletal, CVD), End-user - Global Forecast (2024 - 2032)

出版日期: 2024年04月30日 | 出版商:

Global Market Insights Inc. | 英文 170 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在积极的监管措施和不断增长的研发投资的推动下，2024-2032年全球基因疗法临床试验服务市场的复合年增长率将达到9.2%。

慢性病发病率的不断上升是市场成长的主要动力。据世界卫生组织称，非传染性疾病 (NCD) 每年夺去 4,100 万人的生命，占所有死亡人数的 74%。癌症、心血管疾病和神经退化性疾病等疾病给医疗保健系统带来了沉重负担。传统的治疗程序只提供表面护理或控制症状，而没有解决这些疾病的根本遗传原因。基因疗法提供了一种从根源解决非传染性疾病的有吸引力的方法，提供治癒或缓解疾病的治疗方法。随着全球慢性健康疾病的发病率持续激增，对创新治疗解决方案的需求不断增加，从而推动市场成长。

全球基因疗法临床试验服务业根据服务、治疗领域、最终用户和地区进行分类。

到 2032 年，供应链和物流服务领域的份额将快速增长，因为基于基因的治疗（包括个人化疗法和病毒载体）的复杂性使得必须对供应链运作进行细緻的规划和执行。从采购原材料和管理冷链物流到确保研究产品的按时交付，这些服务对于进行基因疗法临床试验至关重要。服务提供者根据每次试验的具体需求提供全面的供应链解决方案，从而实现高效、合规的试验。

肌肉骨骼疾病领域的基因治疗临床试验服务市占率将在2024 年至2032 年期间大幅成长，因为这些疾病，包括退化性关节疾病、肌肉营养不良和骨骼疾病，给全球医疗保健系统带来沉重负担。基因疗法在认识与这些疾病相关的潜在遗传缺陷方面具有很大的潜力，为疾病修饰和功能改善提供了可能性。因此，专注于基于基因的肌肉骨骼疾病干预措施的临床试验正在获得动力，从而引发了根据这些试验的独特要求量身定制的专业服务的需求。

由于强大的医疗基础设施、严格的监管框架以及不断增长的研发投资，到 2032 年，欧洲基因疗法临床试验服务产业规模将快速成长。英国、德国、法国和瑞士等国家在基因治疗研究和创新方面处于领先地位，拥有充满活力的临床试验服务生态系统。此外，学术机构、生物製药公司和合约研究组织（CRO）之间的合作正在推动该地区基因治疗临床试验的进步。凭藉有利的监管环境和大量的基因治疗候选药物，欧洲市场必将大幅成长。

产业生态系统分析
产业影响力
- 成长动力
  - 临床试验的全球化
  - 遗传疾病和慢性病盛行率不断上升
  - 基因治疗技术不断进步
  - 扩大在肿瘤学和罕见疾病的应用
- 产业陷阱与挑战
  - 严格的监管挑战
成长潜力分析
监管环境
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按服务分类，2021 - 2032 年

主要趋势
临床试验设计与规划
供应及物流服务
监管服务
数据管理和生物统计学
现场管理和监控
其他服务

第 6 章：市场估计与预测：按服务分类，2021 - 2032 年

主要趋势
肿瘤学
血液学
内分泌/代谢紊乱
肌肉骨骼
心血管疾病（CVD）
神经系统疾病
传染病
眼科
免疫学
其他治疗领域

第 7 章：市场估计与预测：按最终用户划分，2021 - 2032 年

主要趋势
製药和生物技术公司
合约研究组织 (CRO)
学术及研究机构
其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Almac Group
Catalent Biologics
Charles River Laboratories International, Inc.
ICON plc
IQVIA Biotech
Labcorp Drug Development
Medpace Holdings, Inc.
Novotech
Parexel International (MA) Corporation
Precision Medicine Group LLC
Sharp Services, LLC
Thermo Fisher Scientific Inc.
Worldwide Clinical Trials

简介目录

Product Code: 9312

Global Gene Therapy Clinical Trial Services Market will record 9.2% CAGR during 2024-2032, driven by positive regulatory initiatives and growing investments in R&D.

The growing incidence of chronic ailments acts as a major growth driver in the market. According to WHO, noncommunicable diseases (NCDs) kill 41 million individuals annually, contributing to 74% of all deaths. Diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions, have placed substantial burden on healthcare systems. Traditional treatment procedures offer superficial care or manage symptoms without addressing the underlying genetic causes of these diseases. Gene therapy provides an appealing approach to tackle NCDs at their roots, offering curative or disease-modifying treatments. As the incidence of chronic health diseases continues to surge globally, there is rising demand for innovative therapeutic solutions, thereby propelling market growth.

Global gene therapy clinical trial services industry is classified based on services, therapeutic areas, end-user, and region.

Supply chain & logistics service segment share will grow rapidly through 2032, as the complex nature of gene-based treatments, including personalized therapies and viral vectors, makes meticulous planning and execution of supply chain operations mandatory. From sourcing raw materials and managing cold chain logistics to ensuring on-time delivery of investigational products, these services are essential to conduct of gene therapy clinical trials. The service providers offer comprehensive supply chain solutions tailored to the specific demand of each trial, thereby allowing efficient and compliant trials.

Gene therapy clinical trial services market share from musculoskeletal disorders segment will witness a decent surge during 2024-2032, as these conditions, including degenerative joint diseases, muscular dystrophies, and bone disorders, impose a heavy burden on healthcare systems globally. Gene therapy holds a lot of potential in acknowledging the underlying genetic defects associated with these disorders, providing the possibility of disease modification and functional improvement. Clinical trials, that are focused on gene-based interventions for musculoskeletal disorders are thus gaining momentum, inducing demand for specialized services tailored to the unique requirements of these trials.

Europe gene therapy clinical trial services industry size will grow rapidly through 2032, owing to the robust healthcare infrastructure, stringent regulatory framework, and growing investments in R&D . Nations such as the United Kingdom, Germany, France, and Switzerland are leading gene therapy research and innovation, harboring a vibrant ecosystem for clinical trial services. Moreover, collaborations between academic institutions, biopharmaceutical companies, and contract research organizations (CROs) are fueling the advancement of gene therapy clinical trials in the region. With a favorable regulatory environment and a large number of gene therapy candidates, Europe market is set to witness substantial growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Globalization of clinical trials
  - 3.2.1.2 Increasing prevalence of genetic and chronic diseases
  - 3.2.1.3 Growing advancements in gene therapy technologies
  - 3.2.1.4 Expanded applications in oncology and rare diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory challenges
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Services, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Clinical trial design & planning
5.3 Supply & logistics services
5.4 Regulatory services
5.5 Data management & biostatistics
5.6 Site management & monitoring
5.7 Other services

Chapter 6 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oncology
6.3 Hematology
6.4 Endocrine/ metabolic disorders
6.5 Musculoskeletal
6.6 Cardiovascular diseases (CVD)
6.7 Neurology disorders
6.8 Infectious disease
6.9 Ophthalmology
6.10 Immunology
6.11 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Pharmaceutical & biotechnology companies
7.3 Contract research organizations (CROs)
7.4 Academic and research institutes
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa